findmyKOL

Michael Weiss, MD

Enriched profile

Professor of Neurology; Director, Division of Neuromuscular Diseases · University of Washington

ORCIDNPI
Region🇺🇸 Seattle, WA · West · United StatesSpecialtyNeurologyFocusALS
Active KOLLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Michael Weiss is Professor of Neurology; Director, Division of Neuromuscular Diseases at University of Washington. OpenAlex indexes 155 publications with 5,515 citations (h-index 35); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 1 Sept 2026

Michael D. Weiss is Professor of Neurology at University of Washington. The public record shows 155 publications with 5,515 citations (h-index 35), centered on ALS. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 14 companies.

  • Most recent indexed publication: 2025 · Muscle & nerve
  • Top research focus: ALS
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 14 companies

Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
ALS5 trialsMotor Neuron Disease5 trialsBrain Diseases3 trialsBrain Ischemia3 trialsHemorrhage1 trialIntracranial Hemorrhages1 trialMovement Disorders1 trialCIDP / Inflammatory Neuropathy1 trialPolyradiculoneuropathy1 trial

Research focus

OpenAlex concept fingerprint
ALS

Drugs & molecules

across trials, industry payments and publications
Zilbrysqgeneric · ZilucoplanClinical trialsIndustry payments8Publications1Rystiggogeneric · RozanolixizumabClinical trialsIndustry payments14PublicationsVyvgartgeneric · Efgartigimod alfaClinical trialsIndustry payments14Publications

Works with

trial sponsors and companies reporting payments
UCB, Inc.Clinical trialsIndustry payments40Argenx Us, Inc.Clinical trialsIndustry payments24Takeda Pharmaceuticals U.S.A., Inc.Clinical trialsIndustry payments19

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
155publications

Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.

5,515citations

Total citations across indexed works.

35h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials
14companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 1 Sept 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

7 more trial records behind the reveal.Reveal →

Industry payments

Updated 1 Sept 2026

14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    75.8%
    Gabapentinoids27.7%
    Gabapentin56%Pregabalin44%
    Part D24 patients
    Other nervous system drugs8.6%
    Radicava Ors100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    11.6%
    Corticosteroid9.6%
    Prednisone100%
    Part D16 patients
    Carnitine Analog2.1%
    Levocarnitine100%
    Part D<11 patients
  • Musculoskeletal

    6.9%
    gamma-Aminobutyric Acid-ergic Agonist5.3%
    Baclofen100%
    Part D<11 patients
    Muscle Relaxant1.6%
    Methocarbamol100%
    Part D<11 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 1 Sept 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 1 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/michael-weiss-38738433

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    sciprofiles.com/profile/2815094

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sciprofiles.com

Mentions by others

where others cite or feature them
  • Other

    emedevents.com/speaker-profile/michael-david-weiss

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 1 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Editorial Board

    Muscle & Nerve

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com
  • Ad hoc reviewer

    Annals of Neurology / Neurology / Journal of Clinical Neuromuscular Disorders

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com
  • Fellow

    American Academy of Neurology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →neurology.uw.edu
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record
  • Top Doctor

    Seattle Magazine

    2025
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Top Doctor

    Castle Connolly

    2025
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Top Doctor

    Seattle Metropolitan Magazine

    2017
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.